doctor remain in firm control, page-20

Zman you are fundamentally correct on the poor performance; some credit does need to be given to the management team for mitigating the negative effect arising from the uncontrollable Intravitreal injections rebate income cut backs; in the 10 Sept 2012 announcement this was first expected to hit Ebitda earnings by up to $3.9m a year! Cost savings across the business assisted to mitigate the reduction in Ebitda. Cheers.